In a significant advancement for the integration of health data, the FHIR (Fast Healthcare Interoperability Resources) annual integration testing has commenced, with the Taiwan National Health Insurance Bureau (NHI) forecasting the rollout of a FHIR-based cancer drug pre-approval mechanism by the end of the year. This development highlights the growing effort in Taiwan to enhance the interoperability and accessibility of healthcare information.
FHIR Integration Testing 2024: A Broader Scope and Enhanced Capabilities
This year’s FHIR integration testing, which started on September 3rd, marks a notable expansion in both scope and complexity. It involves 47 participating organizations, with 14 medical centers, comprising more than half of Taiwan’s medical centers. Additionally, the testing includes 11 teams from Southeast Asian countries, participating in international patient data exchange exercises. The event also introduced 15 tracks, up from previous years, with new additions such as long-term care data exchange, international patient summary exchange, and body activity data exchange.
Cancer Drug Pre-Approval Mechanism: A Step Toward Enhanced Healthcare Efficiency
A key innovation for this year is the inclusion of a FHIR-based cancer drug pre-approval mechanism. This system aims to assist hospitals in producing application documents for review in accordance with the Ministry of Health and Welfare’s TW Core IG (International Guidelines). The mechanism is set to launch by the end of this year, with a further announcement on the FHIR format for major illness data exchange expected in the middle of next year.
FHIR Ecosystem Strengthening Through Open Platforms and Guidelines
In support of this initiative, the Taiwan Medical Image Information Standard Association (MISAT), the host of the integration testing, has established a FHIR Open Login Platform, an index system for users to query applications that have passed the FHIR integration testing and access implementation guidelines.
Benefits of Adopting FHIR for Cancer Drug Review and Beyond
Adopting FHIR for the digitalization of cancer drug review brings several benefits. Firstly, compared to submitting PDF scans, FHIR data is more easily de-identified and can be more efficiently integrated with AI tools to expedite the review process. Hospitals such as Chang Gung Memorial, Taichung Chang Gung Memorial, and Kaohsiung Medical University are already implementing the FHIR cancer drug pre-approval mechanism.
Moreover, the Ministry of Health and Welfare is considering transitioning the paper-based application process for patients after cancer diagnosis to a digital format using FHIR. The FHIR format for this purpose is expected to be published in the middle of next year. The ministry is also collaborating with Tzu Chi Hospital in Hualien on a pilot program for FHIR electronic prescriptions, building on the recent passage of the electronic signature law to enhance the credibility and functionality of electronic prescriptions.
Challenges and Future Directions
While the move towards digitalization offers numerous advantages, several challenges remain. Defining formats and fields is a critical step that the Ministry of Health and Welfare is currently discussing. Achieving a seamless integration of these elements will require ongoing efforts to refine standards and guidelines.
Conclusion
The commencement of this year’s FHIR integration testing signifies a significant stride in enhancing the interoperability of healthcare data in Taiwan, particularly in the context of cancer drug management. With the end-of-year launch of the cancer drug pre-approval mechanism and plans for major illness data exchange, the healthcare sector in Taiwan is poised for a more efficient, accessible, and technologically advanced future.
Views: 0